- draftkings casino games
- Published: 2025-01-11Source: draftkings casino games
Summary Tips: draftkings casino games is referred to as China News Service Guangxi Channel and China News Service Guangxi Network, which is the first news website established by the central media in Guangxi. casino games download Overall positioning: a comprehensive news website with external propaganda characteristics, the largest external communication platform in Guangxi. casino games you can win real money Provide services for industry enterprises, welcome to visit draftkings casino games !
draftkings casino games
GIGATONS: The $100BN Initiative Revolutionizing The Global Net Zero Transition
Daily Post Nigeria Alleged tax evasion: Nigerian Govt sues Nigerdock, seven directors Home News Politics Metro Entertainment Sport News Alleged tax evasion: Nigerian Govt sues Nigerdock, seven directors Published on December 4, 2024 By Matthew Atungwu The Federal Government has filed a six-count criminal charge against Nigerdock Nigeria Limited and seven of its directors over alleged tax evasion. The charge dated November 26 was filed at the Federal High Court sitting in Lagos. The seven directors listed alongside Nigerdock Nigeria Limited in the charge are Maher Jarmakani, Adewale Akanbi, Michael Akhigbe, Daniel Ayscough, Patrick Van Uden, Adebola Adesoye and Rutger Ten Thij. The government, through its lawyer, Moses Ideho, alleged that Nigerdock Nigeria Limited and its directors committed the alleged infractions between 2015 and 2018. Nigerdock Nigeria Limited and its directors were specifically alleged to have, between 2015 and 2018 years of assessment, failed to pay company income tax, tertiary education tax and withholding tax amounting to N68,695,302.53, which are accrued tax liability, accrued interest and penalty. DAILY POST reports that the offences contravene sections 40, 26 and 27 of the Federal Inland Revenue Service Establishment Act 2007 (as amended) and Section 82 of the Companies Income Tax Act (as amended) and are punishable under Section 8. 55 of the Companies Income Tax Act (as amended). Similarly, the offences also violate Section 11 of the Tertiary Education Trust Fund (Establishment) Act 2011. No date has been fixed for the arraignment of all the defendants. Related Topics: Alleged Tax Evasion Nigerdock Don't Miss 16 Days of Activism: Ogun commits to safety for women, girls You may like Alleged tax evasion: FIRS files amended charge against Binance, Gambaryan Alleged Tax Evasion: Kogi Govt seals off UBA headquarters in Lokoja Advertise About Us Contact Us Privacy-Policy Terms Copyright © Daily Post Media Ltd
PROVIDENCE, R.I. – The campus of Butler Hospital is awash in fall colors as the sun moves toward the horizon, on Thursday afternoon, Nov. 7. The shift of nurses, doctors and patients is on the move, the daily changing of the caretakers, as ConvergenceRI struggled on trekking poles to reach the main entrance, on time for an interview with Dr. Linda Carpenter, M.D. One of the pioneering neuroscience researchers at Butler Hospital, Dr. Carpenter is the lead clinical trial researcher on a new, take-home device (Relivion) created by Neurolief to treat major depressive disorder, a chronic and recurring condition that afflicts millions. The interview took place in Dr. Carpenter’s office at Butler Hospital, a portal into a space defined by stylish design and acute attention to detail. Dr. Carpenter is wearing a turquoise scarf that depicts the brain’s synapse structure, replete with dendrites and axons depicted in black. Two days before the interview, former President Donald Trump had been elected the 47th President of the United States, as if the entire nation had been victimized by a mass psychosis where facts no longer seemed to matter. That evening, members of the Rhode Island Senate would convene in a caucus that replicated a medical intervention, as Senators endorsed the continued leadership of Senate President Dominick Ruggerio, despite indications that his chronic health conditions had taken a severe toll. Earlier this summer, ConvergenceRI had conducted an interview with Dr. Carpenter, “Listening to what your brain is telling you,” following her being awarded the Clinical Transcranial Magnetic Stimulation Society Gold Medal. Dr. Carpenter serves as director of the Transcranial Magnetic Stimulation Clinic and Neuromodulation Research Facility at Butler Hospital, a division of Care New England. ConvergenceRI: I am amazed at the latest work, which seems to be just remarkable, in terms of its groundbreaking nature of treatment: The idea that people can have a take-home device that can help them with their treatment of drug-resistant depression. The treatment moves forward in such a way that it may help patients to overcome everything from long-term depression to migraines. CARPENTER: Right. The particular device that we are talking about today which is the subject of clinical trial that we just finished, is the same device that they have already gotten approved for migraines, but the stimulation pattern that it gives for depression is different. You would use this device [taking off her glasses to put on the device to model it], they may look the same, but the stimulation of the prescription , if you will, would be different for migraine than it is for depression. But, it is incredibly exciting, because we don’t yet have any FDA-approved home-use devices for depression. ConvergenceRI: My first question to you is, “How would I be able to get one of these devices?” How would I qualify? Are the clinical trials’ hurdle now over? CARPENTER: The clinical trial was conducted at multiple sites around the country, and I think we also had an Israeli site [the Relivion corporate headquarters are based in Israel with a facility in Florida]. The clinical trial proved the efficacy [of the device] by randomizing people in active or sham, right? The data demonstrated a superior outcome for the people who had active [devices]. At this point, the whole package of results has gone to the FDA, maybe about a month ago. And, they are processing it. Before the FDA started this trial, they gave this company what is known as a “breakthrough designation,” to help them get onto a fast track for going through the regulatory process, because they identified a need for patients with treatment-resistant depression to have [access to a device] at home. Many of [the patients] can’t come to our clinic five days a week for TMS [transcranial modulation stimulation], or they can’t come in for ECT [electro-convulsive therapy]; you would have to have someone drive [the patient] here and then drive them home. The FDA identified the need and put [the firm] on fast track. The company expects, and I don’t work for the company, but I think they expect to receive FDA approval in early 2025. And then, when that happens, they can commercially market the device. Now, how will that work? I don’t know. This is the first of its type, There are a couple different of ways that this can go. It could be that you come to your doctor’s office, they supervise you using it a couple of times until they are confident that you can use it properly. And then you take home the device, use it, come back, check in every two or three or four weeks, something like that. There is also this question of durable medical equipment, which is out of my wheelhouse and how it would work. Which is where you are a clinic and you actually sell the device to the patient. You have a stock of them. I don’t know what the business model will look like. What I do know is that it’s a prescription device . So, you will have to be monitored by a doctor. It doesn’t mean that it has to be a psychiatrist. You could go to a primary care doctor. But, when it first rolls out, because it is FDA-approved for people who have not gotten better with at least one anti-depressant medication, it will b prescribed typically by a psychiatrist at first, I think. And as broadly as it can be disseminated, that would be great. Because the goal would be to reach all of those patients who can’t come to a specialty clinic. And there are a lot of those. If you think about, when we talk about treatment resistant depression, basically about a third of patients don’t get better with standard anti-depressant treatment. And, that’ a huge number; it’s millions of patients, [looking it up on her computer]. There are some 21 million patients with depression, 9 million being treated with anti-depressants, and 3 million meet this criteria for treatment resistant depression if they don’t get better with a standard anti-depressant. We are looking to find and implement a treatment that would be more convenient and accessible – and I am very excited about that. ConvergenceRI: For me as the journalist, the question is: How could I get one of these devices and write about it, and perhaps become part of the follow-up. The goal would be, that as much as a scientific endeavor, I think that for people to understand what is going on, it might be helpful to have a journalist who can write about the experience and share that... CARPENTER: ...It would be fantastic. ConvergenceRI: ...in a comprehensive fashion, I am willing to raise my hand... CARPENTER: ...And volunteer? ConvergenceRI: I would volunteer to become a patient, or whatever is required, to do this, because I think for all the studies you can do, having someone to actually talk about it in a cogent fashion is intriguing to me. CARPENTER : Yes. You can go onto the company’s website and get a prescription for the migraine device. And, I don’t how you do that, I just noticed this (Relivion website for migraine) today, and I think you can purchase it and have it sent to you, and it would be very similar. You would get the experience of what it is like; they have a prescription and then there are accessories. ConvergenceRI: Would that come from through my primary care physician? CARPENTER: I was just looking to see if you could get a prescription under the migraine indication. The trial would go on for 60 days. This is a brand new website, (there is a listing, “Getting started. Telehealth and find a doctor.”) You might b able to interact with this website and get one for a migraine, with a telehealth physician. It looks like they give you ways to do that. ConvergnceRI: I will consider following up with that. From what you have described, it seems like it is a major breakthrough in treatment, with the possibility that this device will be something that will change the way that depression is treated. And perhaps conditions that are linked to depression, such as obsessive compulsive behavior. CARPENTER: Well, we haven’t tested those other indications. But I think you have the right idea. And, in fact, here are a number of devices, if you just Google them, you can find them. But the difference between this and those [other devices] is that they haven’t been put through large, randomized control trials, which takes a lot of time and a lot of money. ConvergenceRI: Have you gone through Phase I, Phase II, and Phase III clinical trials? CARPENTER: The clinical trials design are not the same for drugs as they are for devices. This would be a device that they tested it in an early pilot study. And, they have done all their safety testing before they came to this clinical trial. And, then, I guess, after FDA approval, this is all that will likely be needed according to the FDA to get the clearance. And then, after the clearance, there will be a lot of questions we need to address. We studied this, with people using it every day, active or sham, for a period of eight weeks. And then, what happened in this clinical trial, at the end of eight weeks, you got to crossover and go to active, if you had gotten the sham, and if you had already got active for eight weeks, you could, continue with eight more weeks of active. There were a number of questions built into [the study]. One, if you aren’t all the way better by eight weeks, and you keep going, will you get more people into remission? And, the answer to that question was yes, because more people kept getting better. And the other question was: If you had sham for the first eight weeks, and now you get the real device, can you replicate that the same percent of people were getting better, and we did. But some of the questions we haven’t answered are: OK, we’ve had people using the device for up to 16 weeks, what does the maintenance look like? Do you stop using it? Do you continue to use it? Do you continue to use it less often? How long will it last? Is it something that you are going to pick up when you start to slip and your [depressive] symptoms start to come up again? As soon as the FDA approval happens, then those will be next types of studies that we are doing. And also, we will be doing more mechanism of action studies. To do scans, before and after treatment, to look at how is it changing connections in the brain, and the way it does. ConvergenceRI: How has it changed your life? You have spent a large amount of time working on this, to see it come to creation. To now have a device that is sitting on front of you on your desk, and it seems to work, what is that like for you as a researcher, as a neuroscientist? CARPENTER: It is really exciting. I am very big on “the bench to bedside.” Getting all the way to implementation is something that I really, really enjoy. You know, a few of the hurdles that lay ahead are that this is a small, start-up company that is looking for a big company such as Pfizer to buy them and co-license it to help facilitate the next bunch of clinical trials that need to happen to answer all these additional questions. A lot of this is now in the hands of the device manufacturer, to take the next big steps to help get the device out there. I’m thrilled to be able to talk about it. I am thrilled to know that it works and to recommend it. But, access is so important. And, like all these other new treatments, if people can’t afford them, if health insurance doesn’t cover it... There needs to be access. I am just really hopeful that the pieces fall into place and that they are taken care of, because that is not [the focus of] my work. My work is the scientific work. To get it to implementation, so I can see patients using it. And not just in my clinical trials. We want people to be able to be use it; I think that will take some time. To answer your question directly, there is a little bit of antsy-ness about wanting to keep moving forward, and doing the next thing, to get their money and to get their companies and their commercial model all built. But, it’s exciting. It’s exciting to have been a part of designing the trial to help pick the sites, and make sure that it was conducted with scientific rigor. And to have good data. Because, you know, there are a number of devices out there. Congess passed a law in 1972 that said the FDA will regulate medical devices. And, ever since then, all the biomedical devices go through FDA. But, there were a bunch of devices on the market before 1972. And they were grandfathered in. They have been able to market themselves legally, without ever doing clinical trials, So there are all these devices that patients can get that they advertise for depression or for anxiety or pain, or to improve your dreaming, or something. But they just don’t have the science behind them. Psychiatrists and other physicians tend not to prescribe them; patients sometimes find them and ask, “Will you sign this form I got online?” But they haven’t really been incorporated into the mainstream of treatment because they haven’t had the science. So now, we have the first one with the science. And that is really exciting. I would like to see it become used as a regular treatment for depression. ConvergenceRI: What does it feel like for you to be able to help direct the first of its kind device with the promise of something to be so helpful to people, who are often struggling to get by day-today? CARPENTER: It feels great. It feels really great. We all want to do something, you work with patients, and you are experiencing their suffering, and the disabling nature of the depression. And, the problems with side effects. And, the burdens on families and the economy. It feels great to have something. It will feel greater when I can go, here you are. There are so many people who were involved with the device. I didn’t design it; I didn’t invent it. And, the company did really elegant work in putting it together. It has a really elegant interaction with your smart phone that walks you through how to use it, that checks to make sure that the device is on right, and that sends the information to the cloud that I can look at on a dashboard to see if the patient is using the device safely. But, you know, we are not completely at the finish line until it is disseminated. ConvergenceRI: Let me go back and ask about what is actually happening in the brain with the device. And please correct me if I get this wrong. The idea is what you are working with is the way that the brain can reconfigure the way that the synapses and the neurons fire, essentially that there is a learned pattern that takes place, so if you fire the sequence enough times, it becomes the learned pattern in the brain, and it doesn’t go back to all of the intermediate steps. It goes from A to F, without having gone through B, C, D, and E to get to F. What the device seems to be doing is retraining , if that is the right “verb” to use, to get the neurons to fire differently. CARPENTER: Right. ConvergenceRI: To take the “memories” that are contained, if “memory” is the right word, of what gets lost in the translation of the firing of the synapse. Is that accurate? CARPENTER: That’s a good way to think about it. Think about it like a computer. The computer has all these different parts that have to interact and, if one part breaks down, then the other parts might go around that part. This part might have the control of that part, like a circuit board. Think of depression like a circuit board. And just like you said, A, B, C, and D. And the circuits are connected by synapses, neurons and synapses, right? And so, like you said, if the part of the reward center and joy is turned off and not coming on, and the fear center and anxiety is on when it shouldn’t be, and the top control isn’t telling the others this isn’t the time to be anxious. This isn’t the time to be turned off, this isn’t the time to be attending – all those different signals. So, we know that there are these functional changes in the brain when someone is depressed. And, by and large, you can see when people get better, although depression has a lot of different versions, right? There are a lot of different versions of depression. If you look at all the different symptoms, and there are lot of different ways that it can look. But, in general, if you think about circuit pathology , that the circuit Is not working properly... ConvergenceRI: Circuit pathology? CARPENTER: Yes. Again, if I have a lot of anxiety in my depression, then my amygdala, its connections to other things are not being regulated. We want our brain to say, “Oh yes, be fearful,” when it is appropriate to be fearful, when you are in a terribly dangerous situation. But not when you are trying to relax, and your reward center should be able to turn on when you experience certain things. And so, negative old memories should stay put, and not come in and re-evaluate what is happening in the present, The question of how the device’s treatment for depression works to fix that is unanswerable. How does psychotherapy fix that? How does ECT fix that? How does medication fix that? What we know is where the device has its actions. Or where EMS has its actions. Or what Prozac sticks to on the molecule, right? And what we know about this device is that it stimulates some peripheral nerves, branches of nerves called the trigeminal nerve in the front and branches of these nerves in the back, and these are right underneath your skin, these nerves are stimulated in this synchronous way, carrying messages down to the brain stem. And, this goes up through a bunch of connections, the solitary tech nucleus, the hypothalamus, and gets into the nodes, as you will, of the circuit. How that fixes the regulation is the question. ConvergenceRI: Am I asking the right questions? CARPENTER: Oh, yes, I think they are great questions. ConvergenceRI: Thanks. Trying to translate what you are saying into language that people can understand, that’s part of the problem. I think I get some of it. But I am very much in awe of what it takes to translate what is happening, and the way that you then see it. There is clearly a difference between causation and correlation. CARPENTER: Just think about Prozac’s impact on the serotonin uptake inhibitors And people said: It sticks on this little thing on the cell and it causes more serotonin to be in the cell. It’s not like we’re all down a quart of serotonin; it still is changing the circuits and how they talk to each other. And sometimes, we act like we know exactly how a treatment works. How does psychotherapy work? And that is really a retraining right? Forcefully creating new habits. ConvergenceRI: How tied into other senses is this work? With psychotherapy, you have to listen. In terms of drug intake, it is all about modulating how we respond to pleasure, versus things that are not pleasurable, and the wirings that enable that to happen. CARPENTER: That’s the black box, the wiring that enables it to happen. So, that when a pleasant thing happens, joy, dopamine, the reward circuit is firing. You see your grandchild, you see your friend. You have a good thing happen. The common bottom line seems to be getting all those different functional areas of the brain to coordinate properly, particularly with top-down control, turning off things that are not appropriate and allowing things that are. When reward circuits are down, people feel apathetic, they feel no interest in things, no drive to pursue things. The last step is making the symptoms go away. Each of the treatments we talked about has a different way of approaching it.Premier League cult hero makes BIZARRE return to management - two days after leaving his previous role following two games in charge
Charter Communications Inc. Cl A stock underperforms Wednesday when compared to competitorsGoogle is interested in building more AI infrastructure in the UK but needs the “right conditions”, the company’s UK boss has said. Debbie Weinstein, the technology company’s UK and Ireland managing director, said Google was “engaged actively” with the Government regarding future infrastructure and investments during a visit to the new AI Campus in north London. The Prime Minister also attended the centre on Wednesday where he said he wanted the UK and London to be the “best place in the world to start and scale” an AI business. The education facility in Somers Town was launched through a partnership between Google, Camden Council and Camden Learning and aims to inspire a new generation of AI talent through educating young people and teachers. Speaking to reporters at the campus, Ms Weinstein said: “We hope to build more here and continue to invest here, we obviously have a huge new facility opening next year or so. “We’d like to build more here, it is true. “We need to have the right conditions for that, which is around sort of energy costs, access to clean energy, and some of the other infrastructure topics we’ve been pretty public about needing to happen here, but we’re engaged actively with the Government, and hope to be able to make more investments in the future.” Ms Weinstein said it was important that AI was “regulated well” because of its power and that the Government had the “right approach” to issues related to the technology and safety in particular. She added that the “challenge and opportunity” of the rapidly evolving technology is to “be bold about taking advantage of the opportunities”, including potential improvements to healthcare. “So right now, I feel that I support regulation of AI in the areas around safety, and I think it’s important that we also get guardrails so that the opportunity can come forward as well,” she said.The AP Top 25 men’s college basketball poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . LEWISTON, N.Y. (AP) — Adam Clark had 18 points in Merrimack’s 80-62 victory over Niagara on Sunday. Clark added nine assists for the Warriors (4-6, 2-0 Metro Atlantic Athletic Conference). Devon Savage scored 18 points, finishing 6 of 10 from 3-point range. Sean Trumper went 6 of 7 from the field (3 for 3 from 3-point range) to finish with 16 points. Jhaylon Martinez led the way for the Purple Eagles (4-6, 1-1) with 14 points and six rebounds. Zion Russell added 13 points and six rebounds. Jaeden Marshall had 11 points. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Hail Flutie: BC celebrates 40th anniversary of Miracle in Miami
NoneOakland County DUI Attorney Paul J. Tafelski Discusses Michigan DUI Laws in Latest ArticleSome tech industry leaders are pushing the incoming Trump administration to increase visas for highly skilled workers from other nations. Related Articles National Politics | Trump threat to immigrant health care tempered by economic hopes National Politics | In states that ban abortion, social safety net programs often fail families National Politics | Trump vows to pursue executions after Biden commutes most of federal death row National Politics | Elon Musk’s preschool is the next step in his anti-woke education dreams National Politics | Trump’s picks for top health jobs not just team of rivals but ‘team of opponents’ The heart of the argument is, for America to remain competitive, the country needs to expand the number of skilled visas it gives out. The previous Trump administration did not increase the skilled visa program, instead clamping down on visas for students and educated workers, increasing denial rates. Not everyone in corporate America thinks the skilled worker program is great. Former workers at IT company Cognizant recently won a federal class-action lawsuit that said the company favored Indian employees over Americans from 2013 to 2022. A Bloomberg investigation found Cognizant, and other similar outsourcing companies, mainly used its skilled work visas for lower-level positions. Workers alleged Cognizant preferred Indian workers because they could be paid less and were more willing to accept inconvenient or less-favorable assignments. Question: Should the U.S. increase immigration levels for highly skilled workers? Economists Caroline Freund, UC San Diego School of Global Policy and Strategy YES: Innovation is our superpower and it relies on people. Sourcing talent from 8 billion people in the world instead of 330 million here makes sense. Nearly half our Fortune 500 companies were founded by immigrants or their children. Growing them also relies on expanding our skilled workforce. The cap on skilled-worker visas has hardly changed since the computer age started. With AI on the horizon, attracting and building talent is more important than ever. Kelly Cunningham, San Diego Institute for Economic Research YES: After years of openly allowing millions of undocumented entrants into the country, why is there controversy over legally increasing somewhat the number having desirable skills? Undocumented immigration significantly impacts lower skill level jobs and wages competing with domestic workers at every skill level. Why should special cases be made against those having higher skills? Could they just not walk across the border anyway, why make it more inconvenient to those with desirable skills? James Hamilton, UC San Diego YES: Knowledge and technology are key drivers of the U.S. economy. Students come from all over the world to learn at U.S. universities, and their spending contributed $50 billion to U.S. exports last year. Technological advantage is what keeps us ahead of the rest of the world. Highly skilled immigrants contribute much more in taxes than they receive in public benefits. The skills immigrants bring to America can make us all better off. Norm Miller, University of San Diego YES: According to Forbes, the majority of billion-dollar startups were founded by foreigners. I’ve interviewed dozens of data analysts and programmers from Berkeley, UCSD, USD and a few other schools and 75% of them are foreign. There simply are not enough American graduates to fill the AI and data mining related jobs now exploding in the U.S. If we wish to remain a competitive economy, we need highly skilled and bright immigrants to come here and stay. David Ely, San Diego State University YES: Being able to employ highly skilled workers from a larger pool of candidates would strengthen the competitiveness of U.S. companies by increasing their capacity to perform research and innovate. This would boost the country’s economic output. Skilled workers from other nations that cannot remain in the U.S. will find jobs working for foreign rivals. The demand for H-1B visas far exceeds the current cap of 85,000, demonstrating a need to modify this program. Executives Phil Blair, Manpower YES: Every country needs skilled workers, at all levels, to grow its economy. We should take advantage of the opportunity these workers provide our employers who need these skills. It should be blended into our immigration policies allowing for both short and long term visas. Gary London, London Moeder Advisors YES: San Diego is a premiere example of how highly skilled workers from around the globe enrich a community and its regional economy. Of course Visa levels need to be increased. But let’s go further. Tie visas and immigration with a provision that those who are admitted and educated at a U.S. university be incentivized, or even required, to be employed in the U.S. in exchange for their admittance. Bob Rauch, R.A. Rauch & Associates NO: While attracting high-skilled immigrants can fill critical gaps in sectors like technology, health care and advanced manufacturing, increasing high-skilled immigration could displace American workers and drive down wages in certain industries. There are already many qualified American workers available for some of these jobs. We should balance the need for specialized skills with the impact on the domestic workforce. I believe we can begin to increase the number of visas after a careful review of abuse. Austin Neudecker, Weave Growth YES: We should expand skilled visas to drive innovation and economic growth. Individuals who perform high-skilled work in labor-restricted industries or graduate from respected colleges with relevant degrees should be prioritized for naturalization. We depend on immigration for GDP growth, tax revenue, research, and so much more. Despite the abhorrent rhetoric and curtailing of visas in the first term, I hope the incoming administration can be persuaded to enact positive changes to a clearly flawed system. Chris Van Gorder, Scripps Health YES: But it should be based upon need, not politics. There are several industries that have or could have skilled workforce shortages, especially if the next administration tightens immigration as promised and expected. Over the years, there have been nursing shortages that have been met partially by trained and skilled nurses from other countries. The physician shortage is expected to get worse in the years to come. So, this visa program may very well be needed. Jamie Moraga, Franklin Revere NO: While skilled immigration could boost our economy and competitiveness, the U.S. should prioritize developing our domestic workforce. Hiring foreign nationals in sensitive industries or government-related work, especially in advanced technology or defense, raises security concerns. A balanced approach could involve targeted increases in non-sensitive high-demand fields coupled with investment in domestic STEM education and training programs. This could address immediate needs while strengthening the long-term STEM capabilities of the American workforce. Not participating this week: Alan Gin, University of San DiegoHaney Hong, San Diego County Taxpayers AssociationRay Major, economist Have an idea for an Econometer question? Email me at phillip.molnar@sduniontribune.com . Follow me on Threads: @phillip0202020 election fraud findings released online and via app
Drama and trauma haunt collegiate gridironWEST PALM BEACH, Fla. (AP) — An online spat between factions of Donald Trump's supporters over immigration and the tech industry has thrown internal divisions in his political movement into public display, previewing the fissures and contradictory views his coalition could bring to the White House. The rift laid bare the tensions between the newest flank of Trump's movement — wealthy members of the tech world including billionaire Elon Musk and fellow entrepreneur Vivek Ramaswamy and their call for more highly skilled workers in their industry — and people in Trump's Make America Great Again base who championed his hardline immigration policies. The debate touched off this week when Laura Loomer , a right-wing provocateur with a history of racist and conspiratorial comments, criticized Trump’s selection of Sriram Krishnan as an adviser on artificial intelligence policy in his coming administration. Krishnan favors the ability to bring more skilled immigrants into the U.S. Loomer declared the stance to be “not America First policy” and said the tech executives who have aligned themselves with Trump were doing so to enrich themselves. Much of the debate played out on the social media network X, which Musk owns. Loomer's comments sparked a back-and-forth with venture capitalist and former PayPal executive David Sacks , whom Trump has tapped to be the “White House A.I. & Crypto Czar." Musk and Ramaswamy, whom Trump has tasked with finding ways to cut the federal government , weighed in, defending the tech industry's need to bring in foreign workers. It bloomed into a larger debate with more figures from the hard-right weighing in about the need to hire U.S. workers, whether values in American culture can produce the best engineers, free speech on the internet, the newfound influence tech figures have in Trump's world and what his political movement stands for. Trump has not yet weighed in on the rift, and his presidential transition team did not respond to a message seeking comment. Musk, the world's richest man who has grown remarkably close to the president-elect , was a central figure in the debate, not only for his stature in Trump's movement but his stance on the tech industry's hiring of foreign workers. Technology companies say H-1B visas for skilled workers, used by software engineers and others in the tech industry, are critical for hard-to-fill positions. But critics have said they undercut U.S. citizens who could take those jobs. Some on the right have called for the program to be eliminated, not expanded. Born in South Africa, Musk was once on an a H-1B visa himself and defended the industry's need to bring in foreign workers. “There is a permanent shortage of excellent engineering talent," he said in a post. “It is the fundamental limiting factor in Silicon Valley.” Trump's own positions over the years have reflected the divide in his movement. His tough immigration policies, including his pledge for a mass deportation, were central to his winning presidential campaign. He has focused on immigrants who come into the U.S. illegally but he has also sought curbs on legal immigration , including family-based visas. As a presidential candidate in 2016, Trump called the H-1B visa program “very bad” and “unfair” for U.S. workers. After he became president, Trump in 2017 issued a “Buy American and Hire American” executive order , which directed Cabinet members to suggest changes to ensure H-1B visas were awarded to the highest-paid or most-skilled applicants to protect American workers. Trump's businesses, however, have hired foreign workers, including waiters and cooks at his Mar-a-Lago club , and his social media company behind his Truth Social app has used the the H-1B program for highly skilled workers. During his 2024 campaign for president, as he made immigration his signature issue, Trump said immigrants in the country illegally are “poisoning the blood of our country" and promised to carry out the largest deportation operation in U.S. history. But in a sharp departure from his usual alarmist message around immigration generally, Trump told a podcast this year that he wants to give automatic green cards to foreign students who graduate from U.S. colleges. “I think you should get automatically, as part of your diploma, a green card to be able to stay in this country," he told the “All-In" podcast with people from the venture capital and technology world. Those comments came on the cusp of Trump's budding alliance with tech industry figures, but he did not make the idea a regular part of his campaign message or detail any plans to pursue such changes.
Trudeau says fall of Assad 'ends decades of brutal oppression' for SyriaNone
